Quantcast
Last updated on May 19, 2013 at 9:20 EDT

Latest Star Scientific Inc. Stories

2013-03-19 08:27:35

GLEN ALLEN, Va., March 19, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI), through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Inc., announced today that it has received positive preliminary results from a study investigating the effects of anatabine in an animal model of idiopathic inflammatory bowel disease, Crohn's disease and ulcerative colitis. This study, performed by researchers in the Department of Medicine at the University of Virginia, assessed the...

2013-03-18 16:24:59

GLEN ALLEN, Va., March 18, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today filed its annual financial report on Form 10-K with the Securities & Exchange Commission (SEC). The Company reported net sales for the year ended December 31, 2012 of $6.2 million, a five-fold increase over 2011 net sales of $1.2 million. Fourth-quarter 2012 net sales totaled $2.0 million, compared with $0.8 million in fourth-quarter 2011. Net sales of the Company's Anatabloc® dietary...

2013-03-18 12:28:51

LONDON, March 18, 2013 /PRNewswire/ -- Markets broke their upward streak on the last trading session of the previous week. The bullish sentiments, however, still persists as the major indices are at an all time high. In the coming week, the stocks are expected to show the impact of ongoing budget negotiations. Wall Street expects the bull's run to continue for the foreseeable future. Our research team took a look at the Healthcare sector, more precisely the drug makers...

2013-01-31 12:28:04

GLEN ALLEN, Va., Jan. 31, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces publication of the first peer-reviewed article examining the effects of anatabine in a mouse model of the debilitating autoimmune and neurodegenerative disease multiple sclerosis (MS). The study, conducted by the Company's research partner, The Roskamp Institute, was designed to determine whether anatabine had beneficial effects on the development of experimental autoimmune...

2013-01-28 12:25:55

GLEN ALLEN, Va., Jan. 28, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) commented today on a January 23, 2013, column appearing on TheStreet.com. That piece contains numerous false and misleading statements regarding the Company's anatabine research and the initial results of the ASAP Human Thyroid Health Study released by Star Scientific on January 7, 2013. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) As reported in the Company's January 7, 2013,...

2013-01-24 08:32:15

NEW YORK, Jan. 24, 2013 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Star Scientific, Inc. ("Star Scientific" or the "Company")(NasdaqGM: STSI). The investigation focuses on whether the Company and its executives violated federal securities. On January 23, 2013, shares of Star Scientific fell 31 cents or 11.74% to close at $2.33 after the street.com alleged that the Company...

2013-01-08 00:20:36

GLEN ALLEN, Va., Jan. 7, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) announced today the preliminary results of the Company's ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health. (Logo: http://photos.prnewswire.com/prnh/20120301/NE62741LOGO ) The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary...

2013-01-07 12:25:01

GLEN ALLEN, Va., Jan. 7, 2013 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI), today announced that John Isner, the top-ranked American player on the ATP World Tour, will be the next brand ambassador for the Company's Anatabloc® dietary supplement for anti?inflammatory support. Isner is the second brand ambassador for Anatabloc®, joining PGA Tour champion Fred Couples. (Photo: http://photos.prnewswire.com/prnh/20130107/PH37385) (Photo:...

2012-11-27 12:27:15

GLEN ALLEN, Va., Nov. 27, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today announces that new anatabine research has been accepted by and published online in the European Journal of Pharmacology. In a series of studies, researchers at the Roskamp Institute demonstrated that anatabine can suppress brain inflammation in animal models of Alzheimer's disease, inflammation in the blood in mice, and inflammation induced in human blood once removed from the body. This...

2012-11-09 16:24:23

GLEN ALLEN, Va., Nov. 9, 2012 /PRNewswire/ -- Star Scientific, Inc. (NASDAQ: STSI) today filed its third-quarter 2012 financial report on Form 10-Q with the Securities and Exchange Commission. The Company reported net sales totaling $1.7 million for the three months ended September 30, 2012, compared with net sales of $0.4 million for the same period in 2011. Net sales for the nine months ended September 30, 2012, totaled $4.5 million, compared with $0.8 million for the same period in...